Genetic determinants of the safety of dabigatran (ces1 gene rs2244613 polymorphism) for the Russian population: a multi-ethnic analysis

Dabigatran is a relatively new direct and reversible thrombin inhibitor characterized by a low molecular weight. Dabigatran is included in the latest clinical guidelines as part of anticoagulant therapy for patients with non-valvular atrial fibrillation and an involved high risk of bleeding. Dabigatran can be used in the prevention of venous thromboembolic events in patients who have undergone total knee arthroplasty. However, there is a large interindividual variability in the therapeutic effect of dabigatran, which is reflected in its safety profile. Among the most studied genetic determinants of dabigatran safety has so far been CES1 gene SNP rs2244613. However, the racial and ethnic homogeneity among human subjects participating in NOAC clinical trials creates a problem of an adequate extrapolation of their results on the representatives of other ethnic population groups. In this regard, the aim of this study was to investigate the prevalence of the CES1 gene rs2244613 polymorphism among 12 different ethnic groups residing in Russia to provide a basis for future clinical studies concerned with the investigation of the genetic determinants of dabigatran safety.

CES1, rs2244613, dabigatran, pharmacogenetics

1. Golukhova E.Zh., Grigoryan M.V., Ryabinina M.N. Sovremennye aspekty farmakogenetiki klopidogrela i yego klinicheskoe znacheniye [Current aspects of clopidogrel pharmacogenetics and its clinical significance]. Creative Cardiology. 2014. No. 13. Pp. 39–52. (In Russian).

2. Karkischenko N.N. Mimikrii farmakogenopolimorfizma [Pharmacogenopolymorphism mimicry] // V kn.: Al’ternativy biomeditsiny. Vol. 2. Klassika I al’ternativy farmakotoksikologii. [In the book: Biomedicine alternatives. Part 2. Classical and Alternative Pharmacotoxicology]. Moscow: VPK. 2007. Pp. 111– 158. (In Russian).

3. Mirzaev K.B., Osipova D.V., Kitaeva E.Yu., Shprakh V.V., Abdullaev Sh.P., Andreev D.A., Sychev D.A. Vliyaniye polimorfizma gena CES1 na antiagregantnyy effekt blokatora P2Y12 retseptorov klopidogrela. [CES1 gene polymorphism effect on the antiplatelet activity of clopidogrel]. Clin. Pharmacol. Ther. 2018. Vol. 27. No. 5. Pp. 96–100. (In Russian).

4. Romodanovsky D.P., Khapaev B.A., Ignatiev I.V., Kukes V.G., Karkischenko V.N. Chastoty «medlennykh» allel’nykh variantov genov, kodiruyushchikh izofermenty tsitokhroma P450 CYP2D6,CYP2C19, CYP2C9 u karachayevtsev i cherkesov [Frequencies the «slow» allele variants of the genes coding isoenzymes of cytochrome Р450 CYP2D6, CYP2C19, CYP2C9 in Karachaevs and Circassians]. Biomedicine. 2010. No. 2. Pp. 33–37. (In Russian).

5. Sychev D.A., Kazakov R.E., Otdelenov V.A., Prokofiev A.B. Prikladnye aspekty primineniya farmakogeneticheskogo testirovaniya dlya personalizatsii primeneniya peroralnykh antikoagulyantov v rossiyskikh usloviyakh [Applications of pharmacogenetic testing for personalization of therapy with oral anticoagulants in Russia]. Ration Pharmacother Cardiol. 2013. No. 9(5). Pp. 525–531. (In Russian).

6. Sychev D.A., Levanov A.N., Shelekhova T.V., Bochkov P.O., Denisenko N.Р., Ryzhikova K.A., Mirzaev K.В., Grishina E.A., Gavrilov M.A. Impact of ABCB1 and CES1 genetic polymorphisms on trough steady-state dabigatran concentrations in patients after endoprosthesis of knife join. Atherothrombosis Journal. 2018. No. 1. Pp. 122–130. (In Russian).

7. Chin P.K., Wright D.F., Zhang M., Wallace M.C., Roberts R.L., Patterson D.M., Jensen B.P., Barclay M.L., Begg E.J. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs R. D. 2014. V.14. No. 2. Pp.113–123.

8. Dimatteo C., D’Andrea G., Vecchione G., Paoletti O., Cappucci F., Tiscia G.L., Buono M., Grandone E., Testa S., Margaglione M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb. Res. 2016. No. 144. Pp. 1–5.

9. Eriksson N., Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics. 2012. No. 13(4). Pp. 429–440.

10. Goldhaber S.Z., Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012. No. 379(9828). Pp. 1835–1846.

11. Gu Z.C., Ma X.W., Zheng X.Y., Shen L., Shi F.H., Li H. Left atrial appendage thrombus formation in a patient on dabigatran therapy associated with ABCB1 and CES-1 genetic defect. Front. Pharmacol. 2018. No. 9. P. 491.

12. Jackson L.R. 2nd, Peterson E.D., Okeagu E., Thomas K. Review of race/ethnicity in non-vitamin K antagonist oral anticoagulants clinical trials. J. Thromb. Thrombolysis. 2015. V. 39. No. 2. Pp. 222–227.

13. Mazur-Bialy A.I., Zdebska K., Wypasek E., Undas A. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. Thromb. Res. 2013. No. 131(3). Pp. 279–280.

14. Mirzaev K.B., Sychev D.A., Ryzhikova K.A., Konova O.D., Mammaev S.N., Gafurov D.M., Shuev G.N., Grishina E.A., Sozaeva Z.A. Genetic polymorphisms of cytochrome P450 enzymes and transport proteins in a Russian population and three ethnic groups of Dagestan. Genet. Test. Mol. Biomarkers. 2017. V. 21. No. 12. Pp. 747–753.

15. Pare G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M.D., Axelsson T., Haertter S., Oldgren J., Reilly P., Siegbahn A., Syvanen A.C., Wadelius C., Wadelius M., Zimdahl-Gelling H., Yusuf S., Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013. No. 127. Pp. 1404–1412.

16. Rasmussen H.B., Bjerre D., Linnet K., Jürgens G., Dalhoff K., Stefansson H., Hankemeier T., Kaddurah-Daouk R., Taboureau O., Brunak S., Houmann T., Jeppesen P., Pagsberg A.K., Plessen K., Dyrborg J., Hansen P.R., Hansen P.E., Hughes T., Werge T. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics. 2015. V. 16. No. 6. Pp. 649–665.

17. Reilly P.A., Lehr T., Haertter S., Connolly S.J., Yusuf S., Eikelboom J.W., Ezekowitz M.D., Nehmiz G., Wang S., Wallentin L.; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of LongTerm Anticoagulation Therapy). J. Am. Coll. Cardiol. 2014. No. 63. Pp. 321–328.

18. Shi J., Wang X., Nguyen J.H., Bleske B.E., Liang Y., Liu. L., Zhu H.J. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem. Pharmacol. 2016. No. 119. Pp. 76–84.

19. Stangier J., Eriksson B.I., Dahl O.E., Ahnfelt L., Nehmiz G., Stahle H., Rathgen K., Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. 2005. No. 45. Pp. 555–563.

20. Tang H., Quertermous T., Rodriguez B., Kardia S.L., Zhu X., Brown A., Pankow J.S., Province M.A., Hunt S.C., Boerwinkle E., Schork N.J., Risch N.J. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am. J. Hum. Genet. 2005. V. 76. No. 2. Pp. 268–275.

21. Yunusbayev B., Kutuev I., Khusainova R., Guseinov G., Khusnutdinova E. Genetic structure of Dagestan populations: a study of 11 Alu insertion polymorphisms. Hum. Biol. 2006. V. 78. No. 4. Pp. 465–476.

22. https://www.pharmgkb.org/variant/PA166155037/overview

23. https://www.ncbi.nlm.nih.gov/snp/?term=CES1

24. http://www.who.int/cardiovascular_diseases/ru

25. http://hdl.handle.net/2268/205593